Debiopharm acquires cancer asset IMGN529 from ImmunoGen
The Debiopharm International S.A. unit of Debiopharm Group (Lausanne, Switzerland) said it purchased all rights to cancer therapy DEBIO 1562 (IMGN529) from ImmunoGen Inc. (NASDAQ:IMGN). The deal includes IP covering the development and commercialization of antibody-drug conjugates (ADCs) targeting CD37. DEBIO 1562 is a CD37-targeting antibody linked to ImmunoGen's DM1 cytotoxic agent.
The partners said DEBIO 1562 is ready for Phase II trials for NHL and “particularly” for diffuse large B cell lymphoma (DLBCL). The candidate has completed Phase I testing as monotherapy to treat non-Hodgkin’s lymphoma (NHL) (see BioCentury, June 16, 2014). The product has Orphan Drug designation in the U.S. and EU to treat DLBCL...
BCIQ Target Profiles